Invention Grant
- Patent Title: Osteoclast inhibitors for knee conditions
-
Application No.: US15481330Application Date: 2017-04-06
-
Publication No.: US09884069B2Publication Date: 2018-02-06
- Inventor: Herriot Tabuteau
- Applicant: ANTECIP BIOVENTURES II LLC
- Applicant Address: US NY New York
- Assignee: ANTECIP BIOVENTURES II LLC
- Current Assignee: ANTECIP BIOVENTURES II LLC
- Current Assignee Address: US NY New York
- Agency: Maschoff Brennan
- Agent Brent A. Johnson; Yuefen Zhou
- Main IPC: A61K31/66
- IPC: A61K31/66 ; A61K31/663 ; A61K9/00
Abstract:
Oral, parenteral, and intravenous dosage forms of osteoclast inhibitors, such as neridronic acid, can be used to treat or alleviate pain or related conditions, such as knee pain.
Public/Granted literature
- US20170209469A1 OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS Public/Granted day:2017-07-27
Information query
